Jefferies Maintains Bullish Stance on Dynavax (DVAX) On Heplisav CKD Data Update

Jefferies reiterated their Buy and $6 price target on Dynavax Technologies (NASDAQ: DVAX) after the company provided an incrementally positive update of previous Phase 3 CKD data and from new CKD booster data.

The firm comments, "We remain bullish on the diabetes opportunity and the prospects for a broad label indication for Heplisav. DVAX remains on track to file in the US in May. We continue to believe that DVAX represents attractive risk-reward for investors with significant upside potential on a FDA panel in early 2013."

For an analyst ratings summary and ratings history on Dynavax Technologies click here. For more ratings news on Dynavax Technologies click here.

Shares of Dynavax Technologies closed at $4.70 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• DA Davidson Starts Everus (ECG) at Buy
• Viking Holdings (VIK) PT Raised to $82 at Mizuho